等待開盤 03-26 09:30:00 美东时间
+0.175
+0.51%
BRIEF-Fennec Pharmaceuticals Announces Settlement Agreement Resolving Pedmark Patent Litigation March 16 (Reuters) - Fennec Pharmaceuticals Inc FENC.O : FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION FENNEC PHARMACEUTICALS INC - CIPLA BARRED FROM MARKETING
03-16 20:20
BRIEF-Stellantis Announces Pricing Of Hybrid Bonds Offering March 11 (Reuters) - Stellantis NV STLAM.MI : STELLANTIS ANNOUNCES PRICING OF HYBRID BONDS OFFERING €2.2 BILLION PERPETUAL FIXED RATE RESETTABLE CAPITAL SECURITIES, NON-CALL PERIOD OF 5.25 YEARS, PERPETUAL MATURITY, ANNUAL COUPON OF 6.250%
03-11 15:04
BRIEF-Spirit Airlines Says Co Issuing Recall Notices To Approximately 500 Pilots Who Were Involuntarily Furloughed Between Sept. 1, 2024, And Nov. 1, 2025 March 10 (Reuters) - Spirit Aviation Holdings Inc FLYYQ.PK : SPIRIT AIRLINES: ISSUING RECALL NOTICES TO APPROXIMATELY 500 PILOTS WHO WERE INVOLUN
03-10 21:08
BRIEF-Walker Lane Provides Update On Management Cease Trade Order March 9 (Reuters) - Walker Lane Resources Ltd WLR.V : WALKER LANE PROVIDES UPDATE ON MANAGEMENT CEASE TRADE ORDER WALKER LANE RESOURCES LTD - CONTINUES WORK ON ANNUAL AUDITED FINANCIALS FOR FY ENDED SEPT 30, 2025 Source text: ID:nCNWD
03-09 19:11
BRIEF-Egetis Gets Notice Of Allowance For Patent In The U.S. March 9 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST : RECEIVES NOTICE OF ALLOWANCE FOR MCT8 DEFICIENCY COMPOSITION PATENT IN THE U.S. ANTICIPATES REGULATORY DECISION ON NDA APPLICATION IN SEPTEMBER 2026 EXPECTS RESULTING PATENT WILL
03-09 14:03
BRIEF-Priovant Announces FDA Acceptance And Priority Review Of New Drug Application For Brepocitinib In Dermatomyositis March 3 (Reuters) - Roivant Sciences Ltd ROIV.O : PRIOVANT ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR BREPOCITINIB IN DERMATOMYOSITIS ROIVANT SCIENCES
03-03 20:45
BRIEF-Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo March 1 (Reuters) - Septerna Inc SEPN.O : SEPTERNA ANNOUNCES POSITIVE PHASE 1 DATA FOR SEP-631, AN ORAL MRGPRX2 NAM FOR THE TREATMENT OF MAST CELL-DRIVEN DISEASES, AND OUTLINES INITIAL PHASE 2 DEVELOPMENT STR
03-01 22:47
BRIEF-UBS Sees Gold Reaching $6,200/Oz In Coming Months Feb 24 (Reuters) - UBS: SAYS IT SEES GOLD REACHING $6,200/OZ IN COMING MONTHS AS KEY DRIVERS UNDERPINNING ITS STRONG RALLY OVER THE PAST YEAR REMAIN IN PLACE SAYS TRADE UNCERTAINTY RESURFACED AFTER U.S. PRESIDENT DONALD TRUMP ANNOUNCED A 15% GL
02-24 16:41
BRIEF-Nvidia And OpenAI Near Investment To Replace Unfinished $100 Billion Deal - FT Feb 19 (Reuters) - NVIDIA AND OPENAI NEAR INVESTMENT TO REPLACE UNFINISHED $100BN DEAL - FT NVIDIA IS CLOSE TO FINALISING A $30BN INVESTMENT INTO OPENAI THAT WILL REPLACE THE LONG-TERM $100BN COMMITMENT AGREED BY TH
02-20 08:16
BRIEF-Coatue Management Cuts Share Stake In Nvidia,Tesla,Oracle,dissolves in Pinterest Feb 17 (Reuters) - COATUE MANAGEMENT: COATUE MANAGEMENT CUTS SHARE STAKE IN NVIDIA BY 6.8% TO 9.2 MILLION SHARES - SEC FILING COATUE MANAGEMENT CUTS SHARE STAKE IN TESLA BY 5.1% TO 1.6 MILLION SHARES - SEC FILING
02-18 06:34